Gene and Cell Therapy: Regulatory CMC, Quality Development and Manufacturing

Gene and Cell Therapy: Regulatory CMC, Quality Development and Manufacturing is organized by Vonlanthen Group of Companies This Online CME Conference is held from Jun 23, 2020.

Description:
Preserving swiftly increasing complexity and developing concerns associated to cell & gene therapies, and meeting emerging challenges in the process development, quality / CMC (Chemistry Manufacturing and Controls) technical and regulatory requirements for CGT, best practices to be assessed, novel approaches to be taken, and new paths to be defined.

Gene and Cell Therapy LIVE webinar on 4 June 2020, affiliated with the 2nd Gene and Cell Therapy: Quality Developments to Commercialization Summit, beginning by experts with many years of experience in ATMPs, will address an interactive approach to:

• study from subject-specific case studies,
• transfer professional knowledge and expectations, featuring cell & gene therapy medicinal products,
• receive guidance and competent advice, discussing critical issues and uncertainty in development, manufacturing and control of CGT, as well as clarification of regulatory guidelines.

Participate in the virtually interactive dialogue and practical presentations, exploring industry standards and advancements to:
• stimulate gene and cell product development,
• notice more gene and cell therapy products successfully approved,
• produce a controlled manufacturing process,
• deliver safe and commercially viable CGT products.

Key Practical Learning Points:
• CMC technical and regulatory compliance to enable cell and gene therapy products development roadmap
• Optimised cell and gene therapies method development, manufacturing, cost, and quality efficiency